Ignite Creation Date:
2024-05-05 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00451880
Status:
COMPLETED
Last Update Posted:
2011-10-13
First Post:
2007-03-23
Brief Title:
Study of XL281 in Adults With Solid Tumors
Sponsor:
Exelixis
Organization:
Exelixis
Study Overview
Official Title:
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL281 Administered Orally to Subjects With Solid Tumors
Status:
COMPLETED
Status Verified Date:
2011-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the safest dose of the multiple Raf kinase inhibitor including c-Raf B-Raf and the activated mutant B-RafV600E XL281 how often it should be taken and how well subjects with cancer tolerate XL281 This study will also determine how the body reacts to XL281 when it is taken with and without food and with and without Pepcid famotidine a drug that inhibits stomach acid production
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None